Anti-IL-5 recombinant humanized monoclonal antibody (mepolizumab) for the treatment of atopic dermatitis

J.M. Oldhoff; U. Darsow; T. Werfel; K. Katzer; A. Wulf; J. Laifaoui; D.J. Hijnen; S. Plotz; E.F. Knol; A. Kapp; C.A.F.M. Bruijnzeel - Koomen; J. Ring; M.S. de Bruin-Weller

doi:10.1111/j.1398-9995.2005.00791.x

Anti-IL-5 recombinant humanized monoclonal antibody (mepolizumab) for the treatment of atopic dermatitis

J.M. Oldhoff, U. Darsow, T. Werfel, K. Katzer, A. Wulf, J. Laifaoui, D.J. Hijnen, S. Plotz, E.F. Knol, A. Kapp, C.A.F.M. Bruijnzeel - Koomen, J. Ring, M.S. de Bruin-Weller

Dermatology and Allergology

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

BACKGROUND: Eosinophils may play an important role in the pathogenesis of atopic dermatitis (AD). Interleukin-5 is essential for eosinophil growth, differentiation and migration. A monoclonal antibody to human interleukin-5 (mepolizumab) was developed for atopic diseases. This study was designed to study the effect of mepolizumab in AD.

METHODS: Two single doses of 750 mg mepolizumab, given 1 week apart, were studied in patients with moderate to severe AD using a randomized, placebo-controlled parallel group design. The primary endpoint of 'success' to treatment was defined as the percentage of patients with at least 'marked improvement' after 2 weeks as assessed by the Physician's Global Assessment of Improvement (PGA). Furthermore, SCORing AD (SCORAD), pruritus scoring, number of blood eosinophils and serum thymus and activation-regulated chemokine (TARC) values served as secondary endpoints. Fluticasone propionate cream 0.05%, once daily could be used as rescue medication from day 16 if no improvement was recorded.

RESULTS: Eighteen patients received mepolizumab and 22 placebo treatment. Peripheral blood eosinophil numbers were significantly reduced in the treatment group compared with placebo (P < 0.05). No clinical success was reached by PGA assessment (P = 0.115), SCORAD (P = 0.293), pruritus scoring and TARC values in the mepolizumab-treated group compared with placebo. However, modest improvement (<50% improvement) assessed by PGA was scored significantly more in the mepolizumab-treated group compared with placebo (P < 0.05).

CONCLUSION: Two single doses of 750 mg mepolizumab did not result in clinical success in patients with AD, despite a significant decrease in peripheral blood eosinophils.

Original language	English
Pages (from-to)	693-696
Number of pages	4
Journal	Allergy
Volume	60
Issue number	5
DOIs	https://doi.org/10.1111/j.1398-9995.2005.00791.x
Publication status	Published - 2005

Keywords

Adult
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Chemokine CCL17
Chemokines, CC
Dermatitis, Atopic
Double-Blind Method
Eosinophils
Female
Humans
Leukocyte Count
Male
Middle Aged
Severity of Illness Index
Treatment Failure

Access to Document

10.1111/j.1398-9995.2005.00791.x

Cite this

Oldhoff, J. M., Darsow, U., Werfel, T., Katzer, K., Wulf, A., Laifaoui, J., Hijnen, D. J., Plotz, S., Knol, E. F., Kapp, A., Bruijnzeel - Koomen, C. A. F. M., Ring, J., & de Bruin-Weller, M. S. (2005). Anti-IL-5 recombinant humanized monoclonal antibody (mepolizumab) for the treatment of atopic dermatitis. Allergy, 60(5), 693-696. https://doi.org/10.1111/j.1398-9995.2005.00791.x

@article{b217a125397944e8b75efe42b998a9a0,

title = "Anti-IL-5 recombinant humanized monoclonal antibody (mepolizumab) for the treatment of atopic dermatitis",

abstract = "BACKGROUND: Eosinophils may play an important role in the pathogenesis of atopic dermatitis (AD). Interleukin-5 is essential for eosinophil growth, differentiation and migration. A monoclonal antibody to human interleukin-5 (mepolizumab) was developed for atopic diseases. This study was designed to study the effect of mepolizumab in AD.METHODS: Two single doses of 750 mg mepolizumab, given 1 week apart, were studied in patients with moderate to severe AD using a randomized, placebo-controlled parallel group design. The primary endpoint of 'success' to treatment was defined as the percentage of patients with at least 'marked improvement' after 2 weeks as assessed by the Physician's Global Assessment of Improvement (PGA). Furthermore, SCORing AD (SCORAD), pruritus scoring, number of blood eosinophils and serum thymus and activation-regulated chemokine (TARC) values served as secondary endpoints. Fluticasone propionate cream 0.05%, once daily could be used as rescue medication from day 16 if no improvement was recorded.RESULTS: Eighteen patients received mepolizumab and 22 placebo treatment. Peripheral blood eosinophil numbers were significantly reduced in the treatment group compared with placebo (P < 0.05). No clinical success was reached by PGA assessment (P = 0.115), SCORAD (P = 0.293), pruritus scoring and TARC values in the mepolizumab-treated group compared with placebo. However, modest improvement (<50% improvement) assessed by PGA was scored significantly more in the mepolizumab-treated group compared with placebo (P < 0.05).CONCLUSION: Two single doses of 750 mg mepolizumab did not result in clinical success in patients with AD, despite a significant decrease in peripheral blood eosinophils.",

keywords = "Adult, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Chemokine CCL17, Chemokines, CC, Dermatitis, Atopic, Double-Blind Method, Eosinophils, Female, Humans, Leukocyte Count, Male, Middle Aged, Severity of Illness Index, Treatment Failure",

author = "J.M. Oldhoff and U. Darsow and T. Werfel and K. Katzer and A. Wulf and J. Laifaoui and D.J. Hijnen and S. Plotz and E.F. Knol and A. Kapp and {Bruijnzeel - Koomen}, C.A.F.M. and J. Ring and {de Bruin-Weller}, M.S.",

year = "2005",

doi = "10.1111/j.1398-9995.2005.00791.x",

language = "English",

volume = "60",

pages = "693--696",

journal = "Allergy",

issn = "0105-4538",

publisher = "Wiley-Blackwell",

number = "5",

}

TY - JOUR

T1 - Anti-IL-5 recombinant humanized monoclonal antibody (mepolizumab) for the treatment of atopic dermatitis

AU - Oldhoff, J.M.

AU - Darsow, U.

AU - Werfel, T.

AU - Katzer, K.

AU - Wulf, A.

AU - Laifaoui, J.

AU - Hijnen, D.J.

AU - Plotz, S.

AU - Knol, E.F.

AU - Kapp, A.

AU - Bruijnzeel - Koomen, C.A.F.M.

AU - Ring, J.

AU - de Bruin-Weller, M.S.

PY - 2005

Y1 - 2005

N2 - BACKGROUND: Eosinophils may play an important role in the pathogenesis of atopic dermatitis (AD). Interleukin-5 is essential for eosinophil growth, differentiation and migration. A monoclonal antibody to human interleukin-5 (mepolizumab) was developed for atopic diseases. This study was designed to study the effect of mepolizumab in AD.METHODS: Two single doses of 750 mg mepolizumab, given 1 week apart, were studied in patients with moderate to severe AD using a randomized, placebo-controlled parallel group design. The primary endpoint of 'success' to treatment was defined as the percentage of patients with at least 'marked improvement' after 2 weeks as assessed by the Physician's Global Assessment of Improvement (PGA). Furthermore, SCORing AD (SCORAD), pruritus scoring, number of blood eosinophils and serum thymus and activation-regulated chemokine (TARC) values served as secondary endpoints. Fluticasone propionate cream 0.05%, once daily could be used as rescue medication from day 16 if no improvement was recorded.RESULTS: Eighteen patients received mepolizumab and 22 placebo treatment. Peripheral blood eosinophil numbers were significantly reduced in the treatment group compared with placebo (P < 0.05). No clinical success was reached by PGA assessment (P = 0.115), SCORAD (P = 0.293), pruritus scoring and TARC values in the mepolizumab-treated group compared with placebo. However, modest improvement (<50% improvement) assessed by PGA was scored significantly more in the mepolizumab-treated group compared with placebo (P < 0.05).CONCLUSION: Two single doses of 750 mg mepolizumab did not result in clinical success in patients with AD, despite a significant decrease in peripheral blood eosinophils.

AB - BACKGROUND: Eosinophils may play an important role in the pathogenesis of atopic dermatitis (AD). Interleukin-5 is essential for eosinophil growth, differentiation and migration. A monoclonal antibody to human interleukin-5 (mepolizumab) was developed for atopic diseases. This study was designed to study the effect of mepolizumab in AD.METHODS: Two single doses of 750 mg mepolizumab, given 1 week apart, were studied in patients with moderate to severe AD using a randomized, placebo-controlled parallel group design. The primary endpoint of 'success' to treatment was defined as the percentage of patients with at least 'marked improvement' after 2 weeks as assessed by the Physician's Global Assessment of Improvement (PGA). Furthermore, SCORing AD (SCORAD), pruritus scoring, number of blood eosinophils and serum thymus and activation-regulated chemokine (TARC) values served as secondary endpoints. Fluticasone propionate cream 0.05%, once daily could be used as rescue medication from day 16 if no improvement was recorded.RESULTS: Eighteen patients received mepolizumab and 22 placebo treatment. Peripheral blood eosinophil numbers were significantly reduced in the treatment group compared with placebo (P < 0.05). No clinical success was reached by PGA assessment (P = 0.115), SCORAD (P = 0.293), pruritus scoring and TARC values in the mepolizumab-treated group compared with placebo. However, modest improvement (<50% improvement) assessed by PGA was scored significantly more in the mepolizumab-treated group compared with placebo (P < 0.05).CONCLUSION: Two single doses of 750 mg mepolizumab did not result in clinical success in patients with AD, despite a significant decrease in peripheral blood eosinophils.

KW - Adult

KW - Antibodies, Monoclonal

KW - Antibodies, Monoclonal, Humanized

KW - Chemokine CCL17

KW - Chemokines, CC

KW - Dermatitis, Atopic

KW - Double-Blind Method

KW - Eosinophils

KW - Female

KW - Humans

KW - Leukocyte Count

KW - Male

KW - Middle Aged

KW - Severity of Illness Index

KW - Treatment Failure

U2 - 10.1111/j.1398-9995.2005.00791.x

DO - 10.1111/j.1398-9995.2005.00791.x

M3 - Article

C2 - 15813818

SN - 0105-4538

VL - 60

SP - 693

EP - 696

JO - Allergy

JF - Allergy

IS - 5

ER -

Anti-IL-5 recombinant humanized monoclonal antibody (mepolizumab) for the treatment of atopic dermatitis

Abstract

Keywords

Access to Document

Fingerprint

Cite this